Overview of the impact of noninvasive prenatal testing on diagnostic procedures

Prenatal Diagnosis

Volumn 35, Issue 10, 2015, Pages 972-979

  Warsof, Steven L ^a   Larion, Sebastian ^a   Abuhamad, Alfred Z ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMNIOCENTESIS; CHORION VILLUS SAMPLING; CYTOGENETICS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; HUMAN; LABORATORY; NON INVASIVE PROCEDURE; NUCHAL TRANSLUCENCY MEASUREMENT; PHYSICIAN; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; TRISOMY 21; DOWN SYNDROME; FEMALE; MATERNAL SERUM SCREENING TEST; PREGNANCY; PRENATAL CARE; TRENDS;

DOWN SYNDROME; FEMALE; HUMANS; MATERNAL SERUM SCREENING TESTS; PREGNANCY; PRENATAL CARE;

EID: 84943348850     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4601     Document Type: Review

References (69)

1. Wald NJ, Densem JW, Smith D, et al. Four-marker serum screening for Down's syndrome. Prenat Diagn 1994;14:707-16.
2. Bulletins ACOP. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007;109:217-27.
3. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7.
4. Kooij L, Tymstra T, Berg P. The attitude of women toward current and future possibilities of diagnostic testing in maternal blood using fetal DNA. Prenat Diagn 2009;29:164-8.
5. Tischler R, Hudgins L, Blumenfeld YJ, et al. Noninvasive prenatal diagnosis: pregnant women's interest and expected uptake. Prenat Diagn 2011;31:1292-9.
6. Sayres LC, Allyse M, Norton ME, et al. Cell-free fetal DNA testing: a pilot study of obstetric healthcare provider attitudes toward clinical implementation. Prenat Diagn 2011;31:1070-6.
7. Gil MM, Quezada MS, Bregant B, et al. Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. Ultrasound Obstet Gynecol 2013;42:34-40.
8. Taylor JB, Chock VY, Hudgins L. NIPT in a clinical setting: an analysis of uptake in the first months of clinical availability. J Genet Couns 2014;23:72-8.
9. Larion S, Warsof SL, Romary L, et al. Uptake of noninvasive prenatal testing at a large academic referral center. Am J Obstet Gynecol 2014;211:651.e1-7.
10. Sago H, Sekizawa A, Japan NIPT consortium. Nationwide demonstration project of next-generation sequencing of cell-free DNA in maternal plasma in Japan: one-year experience. Prenat Diagn 2014.
11. Zhang H, Gao Y, Jiang F, et al. Noninvasive prenatal testing for trisomy 21, 18 and 13 - clinical experience from 146, 958 pregnancies. Ultrasound Obstet Gynecol 2015.
12. Chandrasekharan S, Minear MA, Hung A, et al. Noninvasive prenatal testing goes global. Sci Transl Med 2014;6:231fs15.
13. Haymon L, Simi E, Moyer K, et al. Clinical implementation of noninvasive prenatal testing among maternal fetal medicine specialists. Prenat Diagn 2014;34:416-23.
14. Allyse M, Sayres LC, Goodspeed TA, et al. Attitudes towards non-invasive prenatal testing for aneuploidy among US adults of reproductive age. J Perinatol 2014; 34: 429-34.
15. Sayres LC, Allyse M, Goodspeed TA, et al. Demographic and experiential correlates of public attitudes towards cell-free fetal DNA screening. J Genet Couns 2014;23:957-67.
16. Lewis C, Hill M, Skirton H, et al. Non-invasive prenatal diagnosis for fetal sex determination: benefits and disadvantages from the service users' perspective. Eur J Hum Genet 2012;20:1127-33.
17. Oxenford K, Silcock C, Hill M, et al. Routine testing of fetal Rhesus D status in Rhesus D negative women using cell-free fetal DNA: an investigation into the preferences and information needs of women. Prenat Diagn 2013;33:688-94.
18. Yi H, Hallowell N, Griffiths S, et al. Motivations for undertaking DNA sequencing-based non-invasive prenatal testing for fetal aneuploidy: a qualitative study with early adopter patients in Hong Kong. PLoS One 2013;8:e81794.
19. Hill M, Fisher J, Chitty LS, et al. Women's and health professionals' preferences for prenatal tests for Down syndrome: a discrete choice experiment to contrast noninvasive prenatal diagnosis with current invasive tests. Genet Med 2012;14:905-13.
20. Benn P, Borell A, Chiu R, et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2013;33:622-9.
21. American College of Obstetricians and Gynecologists. Committee opinion no. 545: noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012;120:1532-4.
22. Abu-Rustum RS. Non-invasive prenatal testing (NIPT): a matter of critical timing. Prenatal Perspect. 2014;2.
23. Allyse M, Sayres LC, King JS, et al. Cell-free fetal DNA testing for fetal aneuploidy and beyond: clinical integration challenges in the US context. Hum Reprod 2012;27:3123-31.
24. Zamerowski ST, Lumley MA, Arreola RA, et al. Favorable attitudes toward testing for chromosomal abnormalities via analysis of fetal cells in maternal blood. Genet Med 2001;3:301-9.
25. Lewis C, Hill M, Silcock C, et al. Non-invasive prenatal testing for trisomy 21: a cross-sectional survey of service users' views and likely uptake. BJOG 2014;121:582-94.
26. Wallerstein R, Jelks A, Garabedian MJ. A new model for providing cell-free DNA and risk assessment for chromosome abnormalities in a public hospital setting. J Pregnancy 2014;2014:962720.
27. Horsting JM, Dlouhy SR, Hanson K, et al. Genetic counselors' experience with cell-free fetal DNA testing as a prenatal screening option for aneuploidy. J Genet Couns 2014;23:377-400.
28. Song K, Musci TJ, Caughey AB. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. J Matern Fetal Neonatal Med 2013;26:1180-5.
29. Garfield S, Armstrong S. Clinical and cost consequences of incorporating a novel non-invasive prenatal test into the diagnostic pathway for fetal trisomies. J Manag Care Med 2012;15:34-41.
30. Larion S, Warsof SL, Romary L, et al. Association of combined first-trimester screen and noninvasive prenatal testing on diagnostic procedures. Obstet Gynecol 2014;123:1303-10.
31. Benn PA, Egan JF, Fang M, et al. Changes in the utilization of prenatal diagnosis. Obstet Gynecol 2004;103:1255-60.
32. Wray AM, Ghidini A, Alvis C, et al. The impact of first-trimester screening on AMA patients' uptake of invasive testing. Prenat Diagn 2005;25:350-3.
33. Chetty S, Garabedian MJ, Norton ME. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn 2013;33:542-6.
34. Pettit KE, Hull AD, Korty L, et al. The utilization of circulating cell-free fetal DNA testing and decrease in invasive diagnostic procedures: an institutional experience. J Perinatol 2014;34:750-3.
35. Friel LA, Czerwinski JL, Singletary CN. The impact of noninvasive prenatal testing on the practice of maternal-fetal medicine. Am J Perinatol 2014;31:759-64.
36. Wax JR, Cartin A, Chard R, et al. Noninvasive prenatal testing: impact on genetic counseling, invasive prenatal diagnosis, and trisomy 21 detection. J Clin Ultrasound 2015;43:1-6.
37. Platt LD, Janicki MB, Prosen T, et al. Impact of noninvasive prenatal testing in regionally dispersed medical centers in the United States. Am J Obstet Gynecol 2014;211:368.e1-7.
38. Okun N, Teitelbaum M, Huang T, et al. The price of performance: a cost and performance analysis of the implementation of cell-free fetal DNA testing for Down syndrome in Ontario, Canada. Prenat Diagn 2014;34:350-6.
39. Neyt M, Hulstaert F, Gyselaers W. Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis. BMJ Open 2014;4:e005922.
40. Wald NJ, Bestwick JP. Incorporating DNA sequencing into current prenatal screening practice for Down's syndrome. PLoS One 2013;8:e58732.
41. Morris S, Karlsen S, Chung N, et al. Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service. PLoS One 2014;9:e93559.
42. O'leary P, Maxwell S, Murch A, et al. Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies. Aust N Z J Obstet Gynaecol 2013;53:425-33.
43. Manegold-Brauer G, Kang Bellin A, Hahn S, et al. A new era in prenatal care: non-invasive prenatal testing in Switzerland. Swiss Med Wkly 2014;144:w13915.
44. Gil MM, Giunta G, Macalli EA, et al. UK NHS pilot study on cell-free DNA testing in screening for fetal trisomies: factors affecting uptake. Ultrasound Obstet Gynecol 2015;45:67-73.
45. Chan YM, Leung WC, Chan WP, et al. Women's uptake of non-invasive DNA testing following a high-risk screening test for trisomy 21 within a publicly funded healthcare system: findings from a retrospective review. Prenat Diagn 2014.
46. Wax JR, Chard R, Cartin A, et al. Noninvasive prenatal testing: the importance of pretest trisomy risk and posttest predictive values. Am J Obstet Gynecol 2014.
47. Kuppermann M, Pena S, Bishop JT, et al. Effect of enhanced information, values clarification, and removal of financial barriers on use of prenatal genetic testing: a randomized clinical trial. JAMA 2014;312:1210-7.
48. Hill M, Twiss P, Verhoef T, et al. Non-invasive prenatal diagnosis for cystic fibrosis: detection of paternal mutations, exploration of patient preferences and cost analysis. Prenat Diagn 2015.
49. Loane M, Morris JK, Addor MC, et al. Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening. Eur J Hum Genet 2013;21:27-33.
50. Morris JK, Garne E, Wellesley D, et al. Major congenital anomalies in babies born with Down syndrome: a EUROCAT population-based registry study. Am J Med Genet A 2014;164A:2979-86.
51. Buley J. Down's syndrome dwindling. The Copenhagen Post. Denmark (vol 14).
52. Madan K, Breuning MH. Impact of prenatal technologies on the sex ratio in India: an overview. Genet Med 2014;16:425-32.
53. Egan JF, Campbell WA, Chapman A, et al. Distortions of sex ratios at birth in the United States: evidence for prenatal gender selection. Prenat Diagn 2011;31:560-5.
54. Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;119:890-901.
55. Norton ME, Brar H, Weiss J, et al. Non-invasive chromosomal evaluation (NICE) study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;207:137.e1-8.
56. Palomaki GE, Deciu C, Kloza EM, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med 2012;14:296-305.
57. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 88, December 2007. Invasive prenatal testing for aneuploidy. Obstet Gynecol 2007;110:1459-67.
58. Willems PJ, Dierickx H, Vandenakker E, et al. The first 3, 000 non-invasive prenatal tests (NIPT) with the harmony test in Belgium and the Netherlands. Facts Views Vis Obgyn 2014;6:7-12.
59. Royal College of Obstetricians and Gynaecologists (RCOG). Amniocentesis and Chorionic Villus Sampling. Green-top Guideline No. 8. Royal College of Obstetricians and Gynaecologists (RCOG): London, UK; 2010.
60. California Department of Public Health. Prenatal Diagnosis Center Standards and Definitions. California Department of Public Health Genetic Disease Screening Program: Richmond, CA; 2014.
61. Tabor A, Vestergaard CH, Lidegaard O. Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study. Ultrasound Obstet Gynecol 2009;34:19-24.
62. Welch RA, Salem-Elgharib S, Wiktor AE, et al. Operator experience and sample quality in genetic amniocentesis. Am J Obstet Gynecol 2006;194:189-91.
63. Guide to Learning in Maternal-Fetal Medicine. American Board of Obstetrics and Gynecology, 2013.
64. American Board of Obstetrics and Gynecology. 2015 MFM Case List Forms for Oral Examination.
65. 2015 Bulletin for Subspecialty Certification in Maternal-Fetal Medicine. American Board of Obstetrics and Gynecology, 2015.
66. Pittini R, Oepkes D, Macrury K, et al. Teaching invasive perinatal procedures: assessment of a high fidelity simulator-based curriculum. Ultrasound Obstet Gynecol 2002;19:478-83.
67. Nizard J, Duyme M, Ville Y. Teaching ultrasound-guided invasive procedures in fetal medicine: learning curves with and without an electronic guidance system. Ultrasound Obstet Gynecol 2002;19:274-7.
68. Alexander E, Kelly S, Kerzin-Storrar L. Non-invasive prenatal testing: UK genetic counselors' experiences and perspectives. J Genet Couns 2015;24:300-11.
69. Musci TJ, Fairbrother G, Batey A, et al. Non-invasive prenatal testing with cell-free DNA: US physician attitudes toward implementation in clinical practice. Prenat Diagn 2013;33:424-8.